Synopsis
Compound overview
- Research only
- In clinical trials
- Approved outside US
- FDA-approved
What it is
KLOW is a blend product — a single research preparation that combines several peptides, typically GHK-Cu, BPC-157, TB-500 and KPV. It is sold only as a research chemical, is not an approved drug, and is not a single defined compound.
What it does
How it is marketed and what it contains:
- Marketed as a combined repair-and-recovery blend
- Pairs healing-research peptides with the skin peptide GHK-Cu
- Effects reflect its individual ingredients
- Has no studies of the blend itself
How it works
KLOW has no mechanism of its own — it simply delivers several peptides at once. Each ingredient acts through its own pathway, and no research has tested how they behave together.
Safety notes
No blend like KLOW has been tested in human trials, and combining multiple unapproved peptides multiplies the unknowns. Each component carries its own risks, purity varies, and several ingredients are banned in sport. Treat it as fully experimental.
Where to buy KLOW
Pre-measured, dial-adjustable dosing — no reconstitution or measuring. The simplest research format to work with.
Standard lyophilized vial — reconstitute and measure doses yourself. The conventional research format.
Affiliate links — we may earn a commission at no extra cost to you.
Research tool
Reconstitution calculator
Concentration
2.50mg/mL
Draw volume
0.10mL
Insulin units
10IU
Doses/vial
20
Overview
KLOW is a research peptide blend composed of four individual compounds combined in a single lyophilized vial: KPV (a tripeptide derived from alpha-MSH), GHK-Cu (a copper-binding tripeptide), BPC-157 (a synthetic 15-amino-acid stable gastric peptide), and TB-500 (a 17-amino-acid bioactive fragment of thymosin beta-4, the 43-amino-acid actin-binding protein). The blend name is conventionally read as an acronym of the four components, though letter assignments vary across vendor sources and the standard “L” in KLOW is generally understood to denote the GHK-Cu component (alternatively rendered as the L-leucine-style abbreviation in some marketing materials).
Contents
This entry is included for research-literature reference. No published clinical or preclinical research has examined the KLOW blend itself. The rationale for combining these four peptides is derived entirely from the individual component literatures, each of which has its own preclinical record. There are no pharmacokinetic interaction studies for the four-peptide combination, no documented synergy data, and no safety profile specific to the blend as administered.
Researchers working with KLOW are working with a vendor-mixed combination whose total activity is a presumption derived from the underlying component peptides. This page summarizes the component literatures and emphasizes that the absence of blend-specific data is the principal scientific consideration.
Components and Their Individual Research Records
KPV (Lys-Pro-Val)
A three-amino-acid C-terminal fragment of alpha-MSH with anti-inflammatory activity documented in colitis, dermatitis, and mucosal wound healing models. Most extensive preclinical work comes from Lipton and Catania (1997, Immunology Today), Brzoska et al. (2008, Endocrine Reviews), and the Dalmasso group’s IBD studies (2008, Gastroenterology). See the KPV product page for the full mechanism and citation set.
GHK-Cu (Gly-His-Lys-Cu)
A copper-binding tripeptide originally isolated from human serum by Pickart and colleagues. It influences over 4,000 human genes in cultured fibroblasts, with documented effects in wound healing and dermal collagen production. Pickart and Margolina (2018, International Journal of Molecular Sciences) provide a recent review of the mechanistic and dermatological literature.
BPC-157
A synthetic pentadecapeptide derived from human gastric protective protein, characterized at the University of Zagreb by Predrag Sikiric and collaborators in the 1990s. Most extensive preclinical record covers gastrointestinal healing, tendon-to-bone repair, and neuroprotection. See the BPC-157 product page for the full citation set.
TB-500
The synthetic 17-amino-acid LKKTETQ-containing bioactive fragment of thymosin beta-4, a 43-amino-acid actin-binding protein abundant in mammalian tissues. Bock-Marquette et al. (2004, Nature) demonstrated cardioprotective effects in mouse cardiac injury models, and Malinda et al. (1999) characterized wound healing activity.
Mechanistic Speculation for the Combination
The conceptual rationale for the KLOW blend is that the four peptides act through distinct molecular pathways and might be expected to complement one another in tissue repair models. KPV provides anti-inflammatory cytokine modulation; GHK-Cu provides copper-dependent gene expression and collagen support; BPC-157 provides nitric oxide and growth-factor pathway engagement; TB-500 provides actin sequestration and angiogenic support. Whether these distinct mechanisms produce additive, synergistic, antagonistic, or neutral combined effects in any given tissue or condition is not established in the peer-reviewed literature.
Research Status
The KLOW blend is supplied as a research compound by certain vendors. It is not approved by any regulatory body for any indication. The four individual components each have their own research literature and their own safety considerations; the combined product has neither blend-specific clinical data nor pharmacokinetic interaction data. Researchers selecting between the blend and the individual components should be aware that working with the blend means working with a pre-mixed ratio determined by the vendor rather than by published protocol.
Further reading: KLOW Peptide Blend: GHK-Cu, BPC-157, TB-500 and KPV explains how the four components of this blend have been studied.
Dosing in Published Research
About this section
The information below reports dosing only as it appears in published clinical or preclinical research and official regulatory documents. It is provided as published-literature reference material. It is not dosing guidance, not medical advice, and not a recommendation to use or self-administer this compound.
KLOW is a multi-peptide blend, marketed as a combination of several research peptides. None of its components has an established human dose from controlled clinical trials, and the blend itself has not been studied in people. Because no human research defines a dose for this combination, specific figures circulating in vendor material are unverified and are not reported here.
No established human dosing
Because neither the individual components nor the combination have established human dosing, any specific figures circulating online are unverified. This blend is not an approved drug product, and material sold under this name is for laboratory research use only.
Frequently Asked Questions
What is KLOW?
KLOW is a research peptide blend that combines several peptides, typically GHK-Cu, BPC-157, TB-500 and KPV, in a single vial. It is sold only as a research chemical, is not an approved drug, and is not a single defined compound.
How does KLOW work?
KLOW has no mechanism of its own. The conceptual rationale is that its four peptides act through distinct pathways, including anti-inflammatory signalling, copper-dependent gene expression, actin regulation and angiogenesis, and might complement one another in tissue-repair models. This is speculation based on the individual components.
Is KLOW FDA-approved?
No. The KLOW blend is not approved by any regulatory body for any indication. It is supplied only as a research compound by certain vendors.
What does the research say about KLOW?
The combined blend has no blend-specific clinical data. Each of its four component peptides has its own separate research literature, but the KLOW product itself has not been studied.
What are the safety concerns with KLOW?
KLOW has not been evaluated for safety as a product. Each component peptide carries its own separate safety considerations, and combining four research compounds in one preparation means the overall safety profile in humans is unknown.
Research Handling & Storage
Reconstitution (General Guidelines)
Lyophilized peptides are typically reconstituted using bacteriostatic water (0.9% benzyl alcohol). Standard reconstitution protocol:
- Remove the vial from storage and allow it to reach room temperature (20–25°C / 68–77°F) before opening. This typically takes 15–20 minutes.
- Clean the vial stopper with an alcohol prep pad and allow to air dry.
- Using a sterile syringe, slowly inject bacteriostatic water along the inside wall of the vial. Do not spray directly onto the lyophilized powder.
- Gently swirl the vial until the powder is fully dissolved. Do not shake vigorously as this may damage the peptide structure.
- The reconstituted solution should be clear and colorless. Discard if cloudy, discolored, or if particulate matter is visible.
- Label the vial with the reconstitution date, concentration, and your initials.
Common reconstitution volumes in research: 1ml or 2ml of bacteriostatic water per vial, depending on the desired concentration. For example, adding 2ml to a 5mg vial yields a concentration of 2.5mg/ml (2,500mcg/ml).
Storage
- Lyophilized (unreconstituted): Store at -20°C (-4°F) for long-term storage (stable 24+ months), or 2–8°C (36–46°F) refrigerated for short-term storage up to 6 months. Keep desiccated and protected from light.
- Reconstituted: Store at 2–8°C (36–46°F) refrigerated. Use within 4–6 weeks of reconstitution. Do not freeze reconstituted solutions as this may cause degradation.
- Shipping: Lyophilized peptides are generally stable at ambient temperature during transit for several days. Reconstituted solutions should be shipped on ice packs.
Handling Precautions
- Handle with appropriate personal protective equipment (PPE) including nitrile gloves, lab coat, and eye protection.
- Use aseptic/sterile technique when reconstituting and transferring solutions to prevent contamination.
- Avoid repeated freeze-thaw cycles which may denature the compound and reduce potency.
- Keep detailed laboratory records including reconstitution dates, lot numbers, concentrations, and storage conditions.
- Dispose of unused material and sharps in accordance with local regulations and institutional biosafety guidelines.
Stability & Shelf Life
Lyophilized (freeze-dried) peptides are highly stable when stored correctly. At -20°C (-4°F), most peptides retain >95% purity for 24 months or longer. Once reconstituted, the clock starts—proteins in solution are inherently less stable than in dry form. Factors that accelerate degradation include temperature fluctuations, exposure to light, repeated freeze-thaw cycles, bacterial contamination, and oxidation.
Purity & Quality Considerations
Research-grade compounds should be accompanied by a Certificate of Analysis (COA) confirming purity, typically verified by High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS). Look for purity levels of ≥98% for research applications. Third-party testing adds an additional layer of quality assurance. Always verify the source and documentation before using any research compound.
Research Supplies & Resources
Essential supplies and educational resources for peptide research. Links go to Amazon.com.
Lab Supplies
Recommended Reading
Lab Equipment
As an Amazon Associate, peptides.fyi earns from qualifying purchases. Learn more.
